Replies to post #137745 on Biotech Values

[mcbio]

Note they also have a somewhat differentiated (somewhat quicker acting, more selective) ED drug also up for approval. That would be a complicating factor for 3 of the big pharma.

I would just wonder if the ED drug is differentiated meaningfully enough to successfully compete in a generic ED space. (Obviously, the ED drug won't matter as much if Qnexa is approved with a reasonable REMS.)